These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12886047)

  • 1. Tolerability and efficacy of multidose epoetin beta (Reco-Pen) for subcutaneous administration in patients with anemia due to renal failure.
    Kleophas W; Kult J; Kreusser W; Piper C; Plache H; Wunderle P; Fiegel V; Härtl W;
    Kidney Blood Press Res; 2003; 26(3):192-8. PubMed ID: 12886047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of a multidose formulation of epoetin beta in dialysis patients. Collaborative Study Group.
    Raftery MJ; Auinger M; Hertlová M
    Clin Nephrol; 2000 Sep; 54(3):240-5. PubMed ID: 11020023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of recombinant human erythropoietin beta in maintaining common haemoglobin targets in routine clinical practice in Europe: the GAIN study.
    Rath T; Mactier RA; Weinreich T; Scherhag AW;
    Curr Med Res Opin; 2009 Apr; 25(4):961-70. PubMed ID: 19254204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.
    Gertz B; Kes P; Essaian A; Bias P; Buchner A; Zellner D
    Curr Med Res Opin; 2012 Jul; 28(7):1101-10. PubMed ID: 22533679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving therapeutic targets in renal anaemia: considering cost-efficacy.
    Deray G
    Curr Med Res Opin; 2004 Jul; 20(7):1095-101. PubMed ID: 15265254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study.
    Frei U; Kwan JT; Spinowitz BS;
    BMC Nephrol; 2009 Feb; 10():5. PubMed ID: 19243619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoetin-beta (Recormon-Roche) in the treatment of renal anemia in patients with chronic renal failure.
    Tilkian EE; Tzekov VD; Pandeva SM; Kumchev EP; Nikolov DG; Dimitrakov JD; Dimitrakov DD
    Folia Med (Plovdiv); 2000; 42(3):11-5. PubMed ID: 11347329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group.
    Weiss LG; Clyne N; Divino Fihlho J; Frisenette-Fich C; Kurkus J; Svensson B
    Nephrol Dial Transplant; 2000 Dec; 15(12):2014-9. PubMed ID: 11096148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.
    Dunn CJ; Markham A
    Drugs; 1996 Feb; 51(2):299-318. PubMed ID: 8808169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
    Abdelrazik N; Fouda M
    Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of epoetin beta in anemic predialysis patients with chronic renal failure.
    Koch KM; Koene RA; Messinger D; Quarder O; Scigalla P
    Clin Nephrol; 1995 Sep; 44(3):201-8. PubMed ID: 8556837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group.
    Levin NW; Lazarus JM; Nissenson AR
    Am J Kidney Dis; 1993 Aug; 22(2 Suppl 1):3-12. PubMed ID: 8352269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta.
    Gertz B; Kohler E; Kes P; Essaian A; Bias P; Buchner A; Elsässer R
    Curr Med Res Opin; 2010 Oct; 26(10):2393-402. PubMed ID: 20812790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
    Garton JP; Gertz MA; Witzig TE; Greipp PR; Lust JA; Schroeder G; Kyle RA
    Arch Intern Med; 1995 Oct; 155(19):2069-74. PubMed ID: 7575066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose tailoring strategies in haemodialysis patients: a discussion of case histories.
    Kleophas W
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi31-6. PubMed ID: 15958825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.